stockrow
Friday 6 November 2026
Export WGS’s income statement to Excel — free account
GeneDx Holdings Corp.
WGS Healthcare Diagnostics & Research
GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- −257.9%
- Free cash flow
- −585.6%
- Total debt
- +87.4%
Quarter to June 2026, against a year earlier
62.46
1.90
−2.95%
Follow WGS
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 979.45 |
+8 more quarters Free account |
P/S ratio |
4.49 | 4.26 | 8.71 | 7.71 | |
P/FCF ratio |
0.00 | 0.00 | 261.20 | 200.61 | |
P/Operating CF |
(70.38) | (58.13) | (1,205.56) | 196.78 | |
P/B ratio |
8.35 | 7.41 | 12.09 | 10.62 | |
Price to Tangible BV |
20.15 | 17.52 | 29.52 | 29.03 | |
EV/Sales |
4.41 | 4.09 | 8.43 | 7.46 | |
EV/EBITDA |
0.00 | 0.00 | 296.54 | 88.56 | |
EV/Operating CF |
(41.14) | (194.39) | 108.24 | 90.38 | |
EV/FCF |
(26.44) | (63.17) | 252.56 | 193.92 | |
Quick Ratio |
2.90 | 2.83 | 2.26 | 2.47 | |
Current Ratio |
3.30 | 3.09 | 2.46 | 2.71 | |
Net Debt/EBITDA |
3.32 | 1.46 | 16.74 | (32.11) | |
Debt/Assets |
20.11% | 19.11% | 9.20% | 10.44% | |
Debt/Equity |
0.40 | 0.38 | 0.16 | 0.18 | |
Asset Turnover |
0.96 | 0.93 | 0.91 | 0.89 | |
Operating CF/Net income |
1.63 | 0.51 | 0.17 | (2.07) | |
Capex/Depreciation |
(1.51) | (0.95) | (0.63) | (0.95) | |
Interest Coverage |
(14.73) | (80.15) | — | (5.78) | |
Research and Development Expense of Revenue |
17.18% | 19.37% | 20.28% | 16.99% | |
Selling, General and Administrative Expense of Revenue |
66.44% | 72.95% | 61.13% | 58.20% | |
Intangible Assets out of Total Assets |
0.30 | 0.29 | 0.35 | 0.38 | |
Share Based Compensation of Revenue |
5.54% | 8.80% | 8.08% | 9.07% | |
Graham Net Nets |
0.00 | 0.01 | 0.01 | 0.01 | |
Graham Number |
0.00 | 0.00 | 0.00 | 5.01 | |
Earnings Yield |
(5.30%) | (4.14%) | (0.56%) | 0.10% | |
Free Cash Flow Yield |
(3.72%) | (1.52%) | 0.38% | 0.50% | |
Revenue per Share |
3.85 | 3.49 | 4.22 | 4.05 | |
Operating CF per Share |
(0.98) | (1.10) | (0.11) | 0.55 | |
Capex per Share |
(0.34) | (0.22) | (0.15) | (0.21) | |
Free Cash Flow per Share |
(1.32) | (1.32) | (0.26) | 0.33 | |
Cash per Share |
4.46 | 5.82 | 5.98 | 5.39 | |
Shareholders Equity per Share |
8.22 | 8.66 | 10.76 | 10.15 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.22 | 8.66 | 10.76 | 10.15 | |
Free Cash Flow |
(39.09) | (38.86) | (7.44) | 9.60 | |
Working Capital |
171.73 | 182.99 | 159.38 | 149.96 | |
Capital Expenditures |
(10.11) | (6.45) | (4.35) | (6.17) | |
Net Current Asset Value |
9.10 | 18.45 | 52.76 | 35.94 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 301.00 | |
Capex to Sales |
0.09 | 0.06 | 0.04 | 0.05 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 311.39 | |
| Other line items | |||||
Average Receivables |
65.82 | 61.46 | 56.00 | 49.71 | |
Average Payables |
45.67 | 44.21 | 44.31 | 53.38 | |
Average Inventory |
14.88 | 12.45 | 12.30 | 10.67 | |
Average Assets |
472.67 | 476.37 | 471.55 | 451.37 | |
Average Common Equity |
260.68 | 255.76 | 276.71 | 248.38 |
Columns are period end dates · fundamentals updated 26 Oct 2026